Bionano Genomics, Inc. (BNGO)

$1.85

+0.04 (+2.21%)
Rating:
Recommendation:
-
Symbol BNGO
Price $1.85
Beta 2.253
Volume Avg. 7.38M
Market Cap 549.311M
Shares () -
52 Week Range 1.16-4.35
1y Target Est -
DCF Unlevered BNGO DCF ->
DCF Levered BNGO LDCF ->
ROE -38.48% Strong Sell
ROA -36.10% Strong Sell
Operating Margin -
Debt / Equity 14.89% Neutral
P/E -
P/B 1.90 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest BNGO news


DR. R. Erik Holmlin
Healthcare
Medical Instruments & Supplies
NASDAQ Capital Market

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.